查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
慢性腎臟病(CKD)治療藥市場 - 成長，未來展望，競爭分析，2022年～2030年
市場調查報告書
商品編碼
1167480

慢性腎臟病(CKD)治療藥市場 - 成長，未來展望，競爭分析，2022年～2030年

Chronic Kidney Disease (CKD) Drugs Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 119 Pages | 商品交期: 最快1-2個工作天內

價格

慢性腎臟病是非傳染性疾病(NCD)之一。估計全球約8億5000萬人診斷出CKD，哭季在2040年之前在世界將成為第5大死因。牽引CKD治療藥市場的主要原因，是糖尿病，心血管疾病，CKD的盛行率上升，老年人口增加等。

本報告提供全球慢性腎臟病(CKD)治療藥市場市場調查，市場概要，以及各類藥物，各地區的趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 序文

第2章 摘要整理

第3章 慢性腎臟病(CKD)治療藥市場:競爭分析

  • 主要的慢性腎臟病(CKD)治療藥市場供應商的市場定位
  • 慢性腎臟病(CKD)治療藥市場供應商採用的策略
  • 主要的產業策略
  • 階層分析2021年對2030年

第4章 慢性腎臟病(CKD)治療藥市場:常量分析和市場動態

  • 簡介
  • 全球慢性腎臟病(CKD)治療藥的市場價值，2020年～2030年，(100萬美元)
  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 主要課題
    • 主要的機會
  • 促進因素與阻礙因素的影響分析
  • See-Saw分析

第5章 慢性腎臟病(CKD)治療藥市場:各類藥物，2020年～2030年，(100萬美元)

  • 市場概要
  • 成長和收益分析:2021年對2030年
  • 市場區隔
    • 高血壓治療藥
    • 降血脂藥物
    • 貧血治療藥
    • 浮腫治療藥
    • 其他

第6章 北美的慢性腎臟病(CKD)治療藥市場，2020年～2030年，(100萬美元)

第7章 英國及EU的慢性腎臟病(CKD)治療藥市場，2020年～2030年，(100萬美元)

第8章 亞太地區的慢性腎臟病(CKD)治療藥市場，2020年～2030年，(100萬美元)

第9章 南美的慢性腎臟病(CKD)治療藥市場，2020年～2030年，(100萬美元)

第10章 中東、非洲的慢性腎臟病(CKD)治療藥市場，2020年～2030年，(100萬美元)

第11章 企業簡介

  • AbbVie, Inc.
  • Allergan plc.
  • Amgen Inc.
  • AstraZeneca plc.
  • F. Hoffmann-La Roche Ltd
  • FibroGen
  • GlaxoSmithKline plc.
  • Johnson & Johnson
  • Keryx Biopharmaceuticals, Inc.
  • Kissei Pharmaceutical Co., Ltd
  • Pfizer, Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
Product Code: 137463-08-22

Chronic kidney disease (CKD) is also known as chronic kidney failure or renal disease is a condition characterized by a gradual loss of kidney function over time. Key market determinant include rising geriatric populace, increment in prevalence of CKD and favorable insurance policies in developed economies.

The report titled "Chronic Kidney Disease (CKD) Drugs Market - Growth, Future Prospects and Competitive Analysis, 2022-2030" provides detailed insights into key market determinants that impacted the market across geographies and drug types. The report also includes market estimation and forecast for CKD drugs for geographic region.

Chronic kidney disease is a non-communicable disease (NCD). About 850 million people across the world are diagnosed with CKD and is estimated to become the fifth most reason of death in the world by 2040. Key factors driving the CKD drugs market include increasing prevalence of diabetes, cardiovascular disease and CKD and increasing geriatric population. More than 10% of the adults were diagnosed by CKD as per Centers for Disease Control and Prevention (CDC). Increasing prevalence of diabetes and hypertension increased the risk of CKD. About 1 in 3 adults were diagnosed for diabetes and 1 in 5 adults with hypertension. Antihypertensive medication contributed to the largest market in the year 2021. ACE inhibitors and diuretics remain as the first line treatment for CKD. Erythropoietin stimulating agents is also used significantly to deal with anemia which is the common complication among CKD affected patients.

North America was the market leader interms of market revenues for CKD drugs market in 2021 in which the U.S. had the highest contribution of market revenues. The key factors that influenced the U.S. CKD market is the increasing in obesity rate, increasing prevalence of diabetic patient. The pipeline molecule such as ABT-614 (Abbott laboratories), EOS789 (Chugai Pharmaceutical) has significant potential. Increasing funding from government agencies and healthcare organizations had a significant role in driving the market for CKD drugs. As per Centers for Disease Control and Prevention, more than 20 million people are diagnosed with CKD every year in the U.S. Europe remained the second largest market in terms of revenues for CKD drugs. High prevalence rate of CKD was the key driver in Europe. However, the highest growth rate was highest in Asia Pacific during the forecast period on 2022 to 2030. The key drivers in Asia Pacific includes rising incidence of diabetes and cardiovascular disorders, emerging healthcare set up and regulations, increased population, increasing development, per capita income and healthcare spending, increasing government initiatives and increase in awareness level among the public.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Chronic Kidney Disease (CKD) Drugs market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Chronic Kidney Disease (CKD) Drugs market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Class

Antihypertensive

Antihyperlipidemic

Anemia Treatment Drugs

Swelling Treatment Drugs

Other

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Pre COVID-19 situation

Post COVID-19 situation

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Chronic Kidney Disease (CKD) Drugs market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Chronic Kidney Disease (CKD) Drugs market?

Which is the largest regional market for Chronic Kidney Disease (CKD) Drugs market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Chronic Kidney Disease (CKD) Drugs market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Chronic Kidney Disease (CKD) Drugs market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Chronic Kidney Disease (CKD) Drugs Market
  • 2.2. Global Chronic Kidney Disease (CKD) Drugs Market, By Drug Class, 2021 (US$ Million)
  • 2.3. Global Chronic Kidney Disease (CKD) Drugs Market, By Geography, 2021 (US$ Million)
  • 2.4. Attractive Investment Proposition by Geography, 2021

3. Chronic Kidney Disease (CKD) Drugs Market: Competitive Analysis

  • 3.1. Market Positioning of Key Chronic Kidney Disease (CKD) Drugs Market Vendors
  • 3.2. Strategies Adopted by Chronic Kidney Disease (CKD) Drugs Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Chronic Kidney Disease (CKD) Drugs Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Chronic Kidney Disease (CKD) Drugs Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Antihypertensive
    • 5.3.2. Antihyperlipidemic
    • 5.3.3. Anemia Treatment Drugs
    • 5.3.4. Swelling Treatment Drugs
    • 5.3.5. Other

6. North America Chronic Kidney Disease (CKD) Drugs Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
  • 6.3.Chronic Kidney Disease (CKD) Drugs Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.North America
      • 6.3.1.1. U.S.
        • 6.3.1.1.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 6.3.1.2. Canada
        • 6.3.1.2.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 6.3.1.3. Rest of North America
        • 6.3.1.3.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)

7. UK and European Union Chronic Kidney Disease (CKD) Drugs Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
  • 7.3.Chronic Kidney Disease (CKD) Drugs Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.UK and European Union
      • 7.3.1.1. UK
        • 7.3.1.1.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.2. Germany
        • 7.3.1.2.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.3. Spain
        • 7.3.1.3.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.4. Italy
        • 7.3.1.4.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.5. France
        • 7.3.1.5.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.6. Rest of Europe
        • 7.3.1.6.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)

8. Asia Pacific Chronic Kidney Disease (CKD) Drugs Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
  • 8.3.Chronic Kidney Disease (CKD) Drugs Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Asia Pacific
      • 8.3.1.1. China
        • 8.3.1.1.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.2. Japan
        • 8.3.1.2.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.3. India
        • 8.3.1.3.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.4. Australia
        • 8.3.1.4.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.5. South Korea
        • 8.3.1.5.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.6. Rest of Asia Pacific
        • 8.3.1.6.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)

9. Latin America Chronic Kidney Disease (CKD) Drugs Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
  • 9.3.Chronic Kidney Disease (CKD) Drugs Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Latin America
      • 9.3.1.1. Brazil
        • 9.3.1.1.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 9.3.1.2. Mexico
        • 9.3.1.2.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 9.3.1.3. Rest of Latin America
        • 9.3.1.3.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)

10. Middle East and Africa Chronic Kidney Disease (CKD) Drugs Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
  • 10.3.Chronic Kidney Disease (CKD) Drugs Market: By Region, 2020-2030, USD (Million)
    • 10.3.1.Middle East and Africa
      • 10.3.1.1. GCC
        • 10.3.1.1.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 10.3.1.2. Africa
        • 10.3.1.2.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)
      • 10.3.1.3. Rest of Middle East and Africa
        • 10.3.1.3.1. Chronic Kidney Disease (CKD) Drugs Market: By Drug Class, 2020-2030, USD (Million)

11. Company Profile

  • 11.1. AbbVie, Inc.
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Portfolio
    • 11.1.4. Strategic Initiatives
  • 11.2. Allergan plc.
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Portfolio
    • 11.2.4. Strategic Initiatives
  • 11.3. Amgen Inc.
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Portfolio
    • 11.3.4. Strategic Initiatives
  • 11.4. AstraZeneca plc.
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Portfolio
    • 11.4.4. Strategic Initiatives
  • 11.5. F. Hoffmann-La Roche Ltd
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Portfolio
    • 11.5.4. Strategic Initiatives
  • 11.6. FibroGen
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Portfolio
    • 11.6.4. Strategic Initiatives
  • 11.7. GlaxoSmithKline plc.
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Portfolio
    • 11.7.4. Strategic Initiatives
  • 11.8. Johnson & Johnson
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Portfolio
    • 11.8.4. Strategic Initiatives
  • 11.9. Keryx Biopharmaceuticals, Inc.
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Portfolio
    • 11.9.4. Strategic Initiatives
  • 11.10. Kissei Pharmaceutical Co., Ltd
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Portfolio
    • 11.10.4. Strategic Initiatives
  • 11.11. Pfizer, Inc.
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Portfolio
    • 11.11.4. Strategic Initiatives
  • 11.12. Sanofi S.A.
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Portfolio
    • 11.12.4. Strategic Initiatives
  • 11.13. Teva Pharmaceutical Industries Ltd.
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Product Portfolio
    • 11.13.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 2 North America Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 3 U.S. Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 4 Canada Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 5 Rest of North America Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 6 UK and European Union Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 7 UK Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 8 Germany Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 9 Spain Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 10 Italy Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 11 France Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 12 Rest of Europe Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 13 Asia Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 14 China Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 15 Japan Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 16 India Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 17 Australia Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 18 South Korea Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 19 Latin America Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 20 Brazil Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 21 Mexico Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 22 Rest of Latin America Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 23 Middle East and Africa Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 24 GCC Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 25 Africa Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 26 Rest of Middle East and Africa Chronic Kidney Disease (CKD) Drugs Market By Drug Class, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Chronic Kidney Disease (CKD) Drugs Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Chronic Kidney Disease (CKD) Drugs Market: Quality Assurance
  • FIG. 5 Global Chronic Kidney Disease (CKD) Drugs Market, By Drug Class, 2021
  • FIG. 6 Global Chronic Kidney Disease (CKD) Drugs Market, By Geography, 2021
  • FIG. 7 Market Geographical Opportunity Matrix - Global Chronic Kidney Disease (CKD) Drugs Market, 2021
  • FIG. 8 Market Positioning of Key Chronic Kidney Disease (CKD) Drugs Market Players, 2021
  • FIG. 9 Global Chronic Kidney Disease (CKD) Drugs Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 10 Global Chronic Kidney Disease (CKD) Drugs Market, By Drug Class, 2021 Vs 2030, %
  • FIG. 11 U.S. Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 12 Canada Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 13 Rest of North America Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 14 UK Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 15 Germany Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 16 Spain Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 17 Italy Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 18 France Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 19 Rest of Europe Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 20 China Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 21 Japan Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 22 India Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 23 Australia Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 24 South Korea Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Asia Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 26 Brazil Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 27 Mexico Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Latin America Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 29 GCC Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 30 Africa Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030
  • FIG. 31 Rest of Middle East and Africa Chronic Kidney Disease (CKD) Drugs Market (US$ Million), 2020 - 2030